Guardant Health Prices $500 Million Zero-Coupon Convertible Senior Notes Offering Due 2032
Guardant Health, a precision oncology company, has announced the pricing of a private offering of $500 million in aggregate principal amount of 0% convertible senior notes due 2032. The offering represents a significant financing transaction for the company as it manages its existing debt obligations and plans its longer-term capital structure.
The notes are being offered to investors reasonably believed to be qualified institutional buyers under Rule 144A of the Securities Act of 1933, as amended. The issuance and sale of the notes are scheduled to settle on November 16, 2026, subject to customary closing conditions.
In addition to the initial $500 million offering, Guardant Health has granted the initial purchasers an option to purchase up to an additional $50 million in aggregate principal amount of notes. This option may be exercised during a period of 13 days beginning on the date the notes are first issued.
The transaction is structured around zero-coupon convertible senior notes, meaning the notes will not carry regular interest payments. Instead, investors will have the opportunity to convert their holdings into Guardant Health common stock under specified conditions. The offering also includes provisions related to potential redemption, repurchase rights and capped call transactions intended to manage potential shareholder dilution.
Key Terms of the Convertible Notes
The notes will be senior, unsecured obligations of Guardant Health. They will not bear regular interest, and their principal amount will not increase through accretion. The notes are scheduled to mature on May 15, 2032, unless they are converted, redeemed or repurchased earlier in accordance with the terms of the agreement.
The zero-interest structure means that Guardant Health will not be required to make regular coupon payments on the notes. However, the notes remain contractual debt obligations, and the company will be required to meet the repayment or conversion provisions established under the terms of the offering.
The notes will have a conversion rate of 4.7858 shares of Guardant Health common stock for every $1,000 principal amount. Based on this initial conversion rate, the conversion price is approximately $208.95 per share.
This conversion price represents a premium of approximately 35% compared with the last reported sale price of Guardant Health common stock, which was $154.78 per share on November 11, 2026.
The conversion rate will be subject to customary anti-dilution adjustments. These adjustments are designed to account for certain corporate or capital structure changes that could affect the value of the company’s common stock.
Conversion Rights for Noteholders
The notes include specific conditions governing when investors can convert their holdings into Guardant Health common stock.
Before February 15, 2032, noteholders will be permitted to convert all or part of their notes only under certain circumstances outlined in the governing agreement. From February 15, 2032, through the close of business on the second scheduled trading day immediately before the maturity date, investors will have the right to convert their notes at any time at their election.
When a conversion takes place, Guardant Health will determine how the conversion obligation is settled. The company may provide cash, shares of its common stock or a combination of both, depending on its election and the terms of the notes.
This structure gives the company flexibility in managing its financial obligations while providing investors with a potential opportunity to participate in the value of its common stock.
The initial conversion price of approximately $208.95 is higher than the November 11 closing share price of $154.78. As a result, the initial conversion terms reflect a premium over the prevailing share price at the time of pricing.
However, the eventual value received by noteholders will depend on the applicable conversion conditions, the market price of the shares and the settlement method selected by Guardant Health.
Redemption Conditions and Company Flexibility
The offering also establishes conditions under which Guardant Health may redeem the notes before their scheduled maturity.
Generally, the company will not have the right to redeem the notes at its election before November 20, 2029. An exception applies to a specified cleanup redemption provision.
Beginning on November 20, 2029, Guardant Health may redeem all or part of the outstanding notes for cash, subject to the conditions established in the agreement. This redemption right will remain available until the 25th scheduled trading day immediately before the maturity date.
However, the company cannot exercise this provisional redemption right without meeting a specified stock-price condition. The last reported sale price of Guardant Health common stock must exceed 130% of the applicable conversion price for a specified period.
This condition links the company’s ability to redeem the notes to the performance of its common stock. If the required share-price threshold is met, Guardant Health may choose to redeem some or all of the notes for cash.
The redemption price will equal the principal amount of the notes being redeemed, together with any accrued and unpaid special interest and additional interest, if applicable, through the day before the redemption date.
A separate cleanup redemption provision allows Guardant Health to redeem all, but not less than all, of the outstanding notes under specific circumstances. This provision may be used if the aggregate principal amount of notes remaining outstanding is less than $50 million when the company sends the applicable redemption notice and the notes are freely tradable at that time.
The cleanup redemption provision provides a mechanism for addressing a relatively small remaining balance of notes rather than maintaining the debt obligation until its scheduled maturity.
Noteholder Protection in the Event of a Fundamental Change
The terms of the offering also include provisions designed to protect noteholders if Guardant Health undergoes a fundamental change.
A fundamental change, as defined in the indenture governing the notes, may give investors the right to require the company to repurchase their notes for cash, subject to limited exceptions.
If the applicable conditions are met, the repurchase price will equal the principal amount of the notes being repurchased, plus any accrued and unpaid special interest and additional interest, if applicable, through the day before the repurchase date.
This provision gives investors a defined contractual right in certain significant corporate circumstances. It also establishes a potential cash obligation for Guardant Health if noteholders exercise their repurchase rights.
The agreement includes additional conversion-rate protections for certain corporate events occurring before the notes mature. In specified situations, Guardant Health may increase the conversion rate for investors who choose to convert their notes in connection with a qualifying corporate event.
Similar adjustments may apply when the company issues a redemption notice and a noteholder elects to convert notes that have been called, or are deemed to have been called, for redemption during the relevant redemption period.
These provisions are intended to address certain situations in which corporate transactions or redemption activity could otherwise affect the value of the conversion rights available to investors.
Expected Net Proceeds From the Offering
Guardant Health estimates that the offering will generate approximately $489.3 million in net proceeds after deducting initial purchasers’ discounts and commissions and estimated offering expenses.
If the initial purchasers exercise their option to purchase the additional $50 million of notes in full, the company estimates that net proceeds could increase to approximately $538.3 million.
The expected use of the proceeds is closely connected to the company’s existing convertible debt and its planned capped call transactions.
Assuming the additional notes option is exercised in full and the related additional capped call transactions are entered into, Guardant Health expects to use approximately $501.7 million of net proceeds to repurchase for cash approximately $395.2 million in aggregate principal amount of its outstanding 0% convertible senior notes due 2027.
The company intends to use the remaining net proceeds, together with cash on hand, to fund the approximately $51.7 million cost of entering into the capped call transactions.
The planned allocation reflects a combination of debt management and measures intended to address potential dilution associated with the new convertible notes.
Guardant Health has also clarified that the offering is not conditional on the repurchase of the 2027 notes. The announcement does not constitute an offer to repurchase those existing notes.
Repurchase of Existing 2027 Convertible Notes
As part of the financing strategy, Guardant Health expects to conduct privately negotiated transactions to repurchase approximately $395.2 million in aggregate principal amount of its 0% convertible senior notes due 2027.
These transactions are expected to take place concurrently with the pricing of the new offering. They will be conducted through one of the initial purchasers or its affiliate, acting as the company’s agent.
The expected repurchase is designed to address a portion of the company’s existing convertible debt obligations while the company issues a new series of notes with a maturity date in 2032.
The transaction therefore involves both the introduction of new financing and the planned repurchase of a portion of an earlier convertible note issuance.
The expected $501.7 million allocation toward the repurchases assumes that the initial purchasers fully exercise their option to purchase the additional notes and that the additional capped call transactions are entered into.
The company has not presented the new offering as being dependent on completing the 2027 note repurchases. The two activities are related to its broader financing plan, but the offering can proceed independently of those repurchases.
Capped Call Transactions to Help Manage Potential Dilution
In connection with the pricing of the notes, Guardant Health entered into privately negotiated capped call transactions with certain financial institutions, referred to as the option counterparties.
These transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the new notes.
The primary purpose of the capped call arrangements is to help reduce potential dilution to Guardant Health common stock that could result from the conversion of the notes. They are also expected to offset certain cash payments that the company may be required to make above the aggregate principal amount of converted notes, subject to the terms and limitations of the transactions.
The capped call transactions have an initial cap price of $309.56 per share. This represents a 100% premium over Guardant Health’s last reported sale price of $154.78 per share on November 11, 2026.
The cap price is subject to certain adjustments under the terms of the agreements.
The capped call structure is intended to provide a degree of protection against potential dilution or certain additional conversion-related cash payments. However, the protection is limited by the cap and other contractual conditions.
These transactions do not eliminate all potential dilution associated with the convertible notes. Their effectiveness will depend on the applicable market conditions, adjustments and terms of the arrangements.
Market Activity Associated With the Capped Call Transactions
Guardant Health has disclosed that the financial institutions acting as option counterparties may purchase shares of the company’s common stock or enter into derivative transactions as part of establishing their initial hedge positions.
These activities are expected to occur concurrently with or shortly after the pricing of the notes.
The company has also explained that certain investors who agreed to sell their 2027 notes may have previously established hedge positions to manage their exposure to changes in Guardant Health’s share price.
These investors, referred to as hedged holders, may unwind all or part of their hedge positions in connection with the repurchase transactions. Such activity could involve purchasing Guardant Health common stock or entering into or unwinding derivative transactions.
The volume of shares involved in these activities could be substantial compared with the historical average daily trading volume of Guardant Health common stock.
As a result, the transactions could influence the market price of the company’s shares. Depending on the direction and scale of the activity, the transactions could increase the share price or reduce the size of a potential decline.
Guardant Health has stated that these activities could have affected the market price of its common stock during the pricing of the notes. Such movements could also have resulted in a higher effective conversion price for the new notes.
However, the company has emphasized that it cannot predict the magnitude of this market activity or determine its overall impact on the trading prices of the notes or its common stock.
Potential Changes to Hedge Positions After Pricing
The option counterparties and their affiliates may continue to adjust their hedge positions after the offering is priced.
These adjustments may include entering into or unwinding derivative transactions involving Guardant Health common stock, purchasing or selling shares of the company’s common stock, or trading other Guardant Health securities in secondary market transactions.
Such activities may take place following the pricing of the notes and continue before their maturity.
The company expects that hedge-related activity may also occur around each exercise date of the capped call transactions. These exercise dates are expected to fall within the 25-trading-day period beginning on the 26th scheduled trading day before the notes’ maturity date.
Additional hedge adjustments may occur if any portion of the capped call transactions is terminated in connection with a repurchase, redemption or early conversion of the notes.
Guardant Health has cautioned that these activities could cause increases or decreases in the market price of its common stock or the notes.
Changes in the share price may affect whether investors choose to convert their notes. In addition, if hedge-related transactions take place during an observation period associated with a conversion, they could affect the number of shares or the value of the consideration a noteholder receives.
The company has also disclosed a potential risk if a capped call transaction does not become effective. If that happens, the relevant option counterparty may unwind its hedge positions in Guardant Health common stock.
Such activity could adversely affect the value of the company’s common stock and, if the notes have already been issued, the value of the notes.
Private Offering and Securities Restrictions
The notes are being offered only to persons reasonably believed to be qualified institutional buyers under Rule 144A of the Securities Act of 1933.
The offering is being conducted through a private offering memorandum rather than a public registration under the Securities Act.
Neither the notes nor the shares of Guardant Health common stock that may be issued upon conversion have been registered under the Securities Act or other applicable securities laws. They will not be registered as part of this offering.
Consequently, the notes and any shares issued upon conversion may not be offered or sold unless the transaction qualifies for an exemption from registration or is otherwise not subject to the applicable registration requirements.
Guardant Health has also clarified that its announcement does not constitute an offer to sell or a solicitation of an offer to buy the notes or any shares of common stock that may be issued upon conversion.
The announcement should not be interpreted as an offer, solicitation or sale of securities in any state or jurisdiction where such activity would be unlawful before the required registration or qualification under applicable securities laws.
These restrictions reflect the private nature of the transaction and the regulatory framework governing the issuance and resale of the securities.
A Financing Strategy Focused on Long-Term Debt Management
Guardant Health’s $500 million convertible senior notes offering combines new financing with a planned repurchase of existing convertible debt and the implementation of capped call arrangements.
The new notes will mature in 2032 and will carry no regular interest payments. Their initial conversion price of approximately $208.95 per share represents a premium of around 35% over the company’s November 11, 2026, share price.
The company expects net proceeds of approximately $489.3 million, potentially increasing to approximately $538.3 million if the additional notes option is fully exercised.
A substantial portion of the proceeds is expected to support the repurchase of approximately $395.2 million in principal amount of the 2027 convertible notes, while the remaining proceeds and cash on hand are intended to fund the capped call transactions.
The capped call arrangements are designed to reduce potential dilution and offset certain conversion-related cash payments, although their protection is subject to a specified cap and contractual conditions.
The transaction also includes provisions addressing conversion rights, redemption conditions, fundamental changes and potential market activity associated with hedging.
The issuance and sale of the notes are scheduled to settle on November 16, 2026, subject to customary closing conditions. The additional notes option provides the initial purchasers with the opportunity to acquire up to another $50 million in principal amount within the specified 13-day period.
Overall, the offering represents a capital-markets transaction through which Guardant Health is seeking to manage its convertible debt structure while establishing financing obligations extending to 2032. The final financial impact will depend on the completion of the offering, the exercise of the additional purchase option, the execution of the related repurchases and capped call transactions, and the terms governing any future conversion or redemption of the notes.
Source link: https://investors.guardanthealth.com/
